Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease

被引:1
|
作者
Kim, Han-Kyeol [1 ]
Kim, Tae Won [1 ]
Baek, Min Seok [2 ]
Kim, Eung Yeop [3 ]
Sung, Young Hee [4 ]
Lee, Jae Hoon [5 ]
Ryu, Young Hoon [5 ]
Ahn, Sung Jun [6 ]
Yoo, Han Soo [1 ]
Lyoo, Chul Hyoung [1 ]
机构
[1] Yonsei Univ, Gangnam Severance Hosp, Dept Neurol, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Wonju Severance Christian Hosp, Dept Neurol, Wonju Coll Med, Wonju, South Korea
[3] Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiol, Coll Med, Seoul, South Korea
[4] Gachon Univ, Dept Neurol, Gil Med Ctr, Incheon, South Korea
[5] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Radiol, Seoul, South Korea
[6] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Nucl Med, Seoul, South Korea
关键词
dopamine transporter; nigrosome; 1; nigrostriatal degeneration; Parkinson's disease; SMwI; visual assessment; SUBSTANTIA-NIGRA; HUMAN BRAIN; DIAGNOSIS;
D O I
10.1111/ene.15781
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Nigrosome 1 (NG1), a small cluster of dopaminergic cells in the substantia nigra and visible in the susceptibility map-weighted magnetic resonance image (SMwI), is severely affected in Parkinson's disease (PD). However, the degree of nigrostriatal degeneration according to the visibility of NG1 has not yet been well elucidated.Methods We consecutively recruited 138 PD and 78 non-neurodegenerative disease (non-ND) patients, who underwent both F-18-FP-CIT positron emission tomography (PET) and SMwI. Three neurologists and one radiologist evaluated the visibility of NG1 in SMwI. The participants were thereby grouped into visible, intermediate, and non-visible groups. Nigrostriatal dopaminergic input was calculated using the specific binding ratio (SBR) of the F-18-FP-CIT PET. We determined the threshold of regional SBR for discriminating NG1 visibility and the probability for NG1 visibility according to regional SBR.Results Visual rating of NG1 showed excellent interobserver agreements as well as high sensitivity and specificity to differentiate the PD group from the non-ND group. NG1 was visible in seven patients (5.1%) in the PD group, who had relatively short disease duration or less severe loss of striatal dopamine. The threshold of putaminal SBR reduction on the more affected side for the disappearance of NG1 was 45.5%, and the probability for NG1 visibility dropped to 50% after the reduction of putaminal SBR to 41% from the normal mean.Conclusions Almost half loss of nigrostriatal dopaminergic input is required to dissipate the hyperintensity of NG1 on SMwI, suggesting its utility in diagnosing PD only after the onset of the motor symptoms.
引用
收藏
页码:1639 / 1647
页数:9
相关论文
共 50 条
  • [1] Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease
    Svenja Happe
    Paul Christian Baier
    Kathrin Helmschmied
    Johannes Meller
    Klaus Tatsch
    Walter Paulus
    Journal of Neurology, 2007, 254 : 1037 - 1043
  • [2] Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease
    Happe, Svenja
    Baier, Paul Christian
    Helmschmied, Kathrin
    Meller, Johannes
    Tatsch, Klaus
    Paulus, Walter
    JOURNAL OF NEUROLOGY, 2007, 254 (08) : 1037 - 1043
  • [3] The Neuropsychology of Nigrostriatal Dopaminergic Transmission in Parkinson's Disease
    Wallesch, C.
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2011, 79 (12) : 692 - 695
  • [4] Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease
    Drui, G.
    Carnicella, S.
    Carcenac, C.
    Favier, M.
    Bertrand, A.
    Boulet, S.
    Savasta, M.
    MOLECULAR PSYCHIATRY, 2014, 19 (03) : 358 - 367
  • [5] Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease
    G Drui
    S Carnicella
    C Carcenac
    M Favier
    A Bertrand
    S Boulet
    M Savasta
    Molecular Psychiatry, 2014, 19 : 358 - 367
  • [6] Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera, Andrea
    Munoz, Patricia
    Steinbusch, Harry W. M.
    Segura-Aguilar, Juan
    ACS CHEMICAL NEUROSCIENCE, 2017, 8 (04): : 702 - 711
  • [7] Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson’s disease
    Nicolaas I. Bohnen
    Satyanarayana Gedela
    Hiroto Kuwabara
    Gregory M. Constantine
    Chester A. Mathis
    Stephanie A. Studenski
    Robert Y. Moore
    Journal of Neurology, 2007, 254 : 84 - 90
  • [8] Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease
    Bohnen, Nicolaas I.
    Gedela, Satyanarayana
    Kuwabara, Hiroto
    Constantine, Gregory M.
    Mathis, Chester A.
    Studenski, Stephanie A.
    Moore, Robert Y.
    JOURNAL OF NEUROLOGY, 2007, 254 (01) : 84 - 90
  • [9] Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease
    Kim, Mia
    Cho, Ki-Ho
    Shin, Mal-Soon
    Lee, Jae-Min
    Cho, Han-Sam
    Kim, Chang-Ju
    Shin, Dong-Hoon
    Yang, Hyeon Jeong
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 33 (04) : 870 - 878
  • [10] Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease
    Ishibashi, K.
    Kanemaru, K.
    Saito, Y.
    Murayama, S.
    Oda, K.
    Ishiwata, K.
    Mizusawa, H.
    Ishii, K.
    ACTA NEUROLOGICA SCANDINAVICA, 2010, 122 (01): : 46 - 51